<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>肿瘤资讯 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2021-01-22T20:53:08+08:00</updated>
  <subtitle>分享肿瘤领域最新进展，传播正确肿瘤防治理念，提高全社会对肿瘤的关注！新浪微博：@肿瘤资讯</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>【2715】人物专访丨武田中国总裁单国洪：借医改浪潮演绎“5D模型”，迎接创新药最好的时代</title>
    <updated>2021-01-22T18:30:56+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-22:/s/e8s7Ve6riBGwlhKY1EX7Rw</id>
    <link href="https://mp.weixin.qq.com/s/e8s7Ve6riBGwlhKY1EX7Rw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【2021 ASCO-GI】金永东教授对话燕锦教授：晚期结直肠癌安罗替尼一线及维持治疗新探索</title>
    <updated>2021-01-22T18:30:56+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-22:/s/JcT_wLZEWEu148UuL4M9qw</id>
    <link href="https://mp.weixin.qq.com/s/JcT_wLZEWEu148UuL4M9qw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【年度巨制】2020肺癌年终盘点Session 3：优化策略,全程管理:驱动基因阳性Ⅳ期NSCLC之EGFR突变后线治疗研究进展</title>
    <updated>2021-01-22T18:30:56+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-22:/s/yryv7kTkygh_BYorxuYIrQ</id>
    <link href="https://mp.weixin.qq.com/s/yryv7kTkygh_BYorxuYIrQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>“GIST 新时空”专栏 | 钱浩然教授公开课：开关控制抑制剂突破晚期GIST治疗困境</title>
    <updated>2021-01-22T18:30:56+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-22:/s/Q3Tb2RewZgHk1USyOJnOBA</id>
    <link href="https://mp.weixin.qq.com/s/Q3Tb2RewZgHk1USyOJnOBA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【2020年食管癌学术进展年度盘点：放疗篇】放疗联合免疫深耕，赋能食管癌放疗新模式探索——王鑫教授</title>
    <updated>2021-01-22T18:30:56+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-22:/s/Sicd2LPjLPSvCGRXgVnUCw</id>
    <link href="https://mp.weixin.qq.com/s/Sicd2LPjLPSvCGRXgVnUCw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>年度巨制丨「骨与软组织肿瘤药物盘点」SESSION 7：肉瘤的免疫治疗</title>
    <updated>2021-01-22T18:30:56+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-22:/s/iV2TCw1pAB-7Aqn8PRw4xw</id>
    <link href="https://mp.weixin.qq.com/s/iV2TCw1pAB-7Aqn8PRw4xw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>“隔离就是战斗，有问必有所得” | 【6】临近绝经状态，诺雷得®真的必要吗?</title>
    <updated>2021-01-22T18:30:56+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-22:/s/d0JyLYp9xKGWsPkrOEDfUQ</id>
    <link href="https://mp.weixin.qq.com/s/d0JyLYp9xKGWsPkrOEDfUQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>《肿瘤新视角》第三期：一波未平，一波又起—免疫相关不良反应病例解读！</title>
    <updated>2021-01-22T18:30:56+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-22:/s/t-1ipiBFegFDqqYmVvxOSQ</id>
    <link href="https://mp.weixin.qq.com/s/t-1ipiBFegFDqqYmVvxOSQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【2714】COMMF市场及销售分论坛｜圆桌讨论精要（一）</title>
    <updated>2021-01-21T19:46:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-21:/s/L6V2cNIvRLEQWIk4TnJMoQ</id>
    <link href="https://mp.weixin.qq.com/s/L6V2cNIvRLEQWIk4TnJMoQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【2021 ASCO-GI】曾江正教授对话林海锋教授：安罗替尼联合特瑞普利单抗一线治疗不可切除肝癌潜力巨大</title>
    <updated>2021-01-21T19:46:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-21:/s/wSVZnmyl-Po6irO9l5x7lQ</id>
    <link href="https://mp.weixin.qq.com/s/wSVZnmyl-Po6irO9l5x7lQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【年度巨制】2020肺癌年终盘点Session 2：驱动基因阳性Ⅳ期NSCLC之EGFR突变一线治疗研究进展</title>
    <updated>2021-01-21T19:46:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-21:/s/8advB7Nu--_xRIDrQoN_nw</id>
    <link href="https://mp.weixin.qq.com/s/8advB7Nu--_xRIDrQoN_nw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>张翼鷟教授：儿童肿瘤药物临床研究现状与中肿实践</title>
    <updated>2021-01-21T19:46:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-21:/s/1Gw8B3Bv6vTme-Opbs5kEw</id>
    <link href="https://mp.weixin.qq.com/s/1Gw8B3Bv6vTme-Opbs5kEw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>张苏展教授：结直肠癌三线治疗再添有效选择，国产首仿TAS-102（苏远®） “飞入寻常百姓家”</title>
    <updated>2021-01-21T19:46:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-21:/s/A8_WM3n356Tu3pYVCF4rQg</id>
    <link href="https://mp.weixin.qq.com/s/A8_WM3n356Tu3pYVCF4rQg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【说文解泌】多线守护，长期生存！晚期肾癌免疫治疗突破之路</title>
    <updated>2021-01-21T19:46:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-21:/s/CA0as1Dn2zrvunBCHy3yjg</id>
    <link href="https://mp.weixin.qq.com/s/CA0as1Dn2zrvunBCHy3yjg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>BRAF+最前沿月评｜第一期 BRAF+MEK双靶连续剂量是BRAF突变黑色素瘤标准治疗方案</title>
    <updated>2021-01-21T19:46:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-21:/s/2oCK5gA1SHXjf8ZI9URx4Q</id>
    <link href="https://mp.weixin.qq.com/s/2oCK5gA1SHXjf8ZI9URx4Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【用“实例”说话】晚期肝癌伴黄疸，多措并举带来生存获益</title>
    <updated>2021-01-21T19:46:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-21:/s/tUevRS56SIARU1U59DyeAw</id>
    <link href="https://mp.weixin.qq.com/s/tUevRS56SIARU1U59DyeAw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【2713】@所有人，「2020金研奖」十大原创研究人气投票开始！40选10由您决定！</title>
    <updated>2021-01-20T19:28:20+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-20:/s/P8-L-kqn8La_Xk-r2SnEiA</id>
    <link href="https://mp.weixin.qq.com/s/P8-L-kqn8La_Xk-r2SnEiA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【2021 ASCO-GI】孙永琨教授对话依荷芭丽·迟教授：安罗替尼可显著改善RAS/BRAF野生型晚期结直肠癌患者的OS</title>
    <updated>2021-01-20T19:28:20+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-20:/s/PMWOIsXIEjwVrHw73i2KxA</id>
    <link href="https://mp.weixin.qq.com/s/PMWOIsXIEjwVrHw73i2KxA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>人物专访｜百济神州吴清漪：肿瘤新药上市即 “红海”，营销需全渠道广覆盖</title>
    <updated>2021-01-20T19:28:20+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-20:/s/UgCmTFdInjH4Lx67lugf9A</id>
    <link href="https://mp.weixin.qq.com/s/UgCmTFdInjH4Lx67lugf9A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【年度巨制】2020肺癌年终盘点Session 1：风起云涌，花落谁家——早期、局晚期NSCLC研究进展（文末有惊喜）</title>
    <updated>2021-01-20T19:28:20+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-20:/s/jC6moKMczC8lqV3YFHXaZg</id>
    <link href="https://mp.weixin.qq.com/s/jC6moKMczC8lqV3YFHXaZg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>